Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia
Public ClinicalTrials.gov record NCT00495079. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study to Evaluate the Safety and Efficacy of Weekly Doses of Marqibo® (Vincristine Sulfate Liposomes Injection) in Adult Patients With Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Adult Patients With Philadelphia Chromosome-negative ALL Who Failed Two Treatment Lines of Anti-leukemia Chemotherapy
Study identification
- NCT ID
- NCT00495079
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Enrollment
- 65 participants
Conditions and interventions
Conditions
Interventions
- Marqibo® (vincristine sulfate liposomes injection) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2007
- Primary completion
- Aug 7, 2010
- Completion
- Aug 7, 2010
- Last update posted
- Mar 4, 2021
2007 – 2010
United States locations
- U.S. sites
- 18
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC - Norris Cancer Center | Los Angeles | California | 90033 | — |
| UCLA Medical Center | Los Angeles | California | 90095 | — |
| University of California Medical Center | San Francisco | California | 94143 | — |
| Stanford Hospitals and Clinics | Stanford | California | 94305 | — |
| Rocky Mountain Cancer Center | Denver | Colorado | 80218 | — |
| Emory University - Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Loyola University Medical Center | Chicago | Illinois | 60153 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Univesity of Iowa - Hospitals and Clinica | Iowa City | Iowa | 52242 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| New York Medical College | Valhalla | New York | 10595 | — |
| Western Pennsylvania Allegheny Health System | Pittsburgh | Pennsylvania | 15224 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15232 | — |
| University of Texas M.D. Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00495079, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 4, 2021 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00495079 live on ClinicalTrials.gov.